447 related articles for article (PubMed ID: 28384481)
21. Motivation-cognition interaction: how feedback processing changes in healthy ageing and in Parkinson's disease.
Di Rosa E; Schiff S; Cagnolati F; Mapelli D
Aging Clin Exp Res; 2015 Dec; 27(6):911-20. PubMed ID: 25854302
[TBL] [Abstract][Full Text] [Related]
22. Enhanced frontal function in Parkinson's disease.
Cools R; Miyakawa A; Sheridan M; D'Esposito M
Brain; 2010 Jan; 133(Pt 1):225-33. PubMed ID: 19995871
[TBL] [Abstract][Full Text] [Related]
23. Insight into dopamine-dependent planning deficits in Parkinson's disease: A sharing of cognitive & sensory resources.
Pieruccini-Faria F; Jones JA; Almeida QJ
Neuroscience; 2016 Mar; 318():219-29. PubMed ID: 26794593
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic medication increases motivation to exert cognitive control by reducing subjective effort costs in Parkinson's patients.
Bogdanov M; LoParco S; Otto AR; Sharp M
Neurobiol Learn Mem; 2022 Sep; 193():107652. PubMed ID: 35724812
[TBL] [Abstract][Full Text] [Related]
25. Dopamine dependency of cognitive switching and response repetition effects in Parkinson's patients.
Shook SK; Franz EA; Higginson CI; Wheelock VL; Sigvardt KA
Neuropsychologia; 2005; 43(14):1990-9. PubMed ID: 16243049
[TBL] [Abstract][Full Text] [Related]
26. The role of dopamine in the brain - lessons learned from Parkinson's disease.
Meder D; Herz DM; Rowe JB; Lehéricy S; Siebner HR
Neuroimage; 2019 Apr; 190():79-93. PubMed ID: 30465864
[TBL] [Abstract][Full Text] [Related]
27. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
28. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease.
Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
J Neurophysiol; 2010 Feb; 103(2):942-9. PubMed ID: 20018839
[TBL] [Abstract][Full Text] [Related]
29. Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease.
Dan R; Růžička F; Bezdicek O; Roth J; Růžička E; Vymazal J; Goelman G; Jech R
Eur Neuropsychopharmacol; 2019 Nov; 29(11):1258-1272. PubMed ID: 31607424
[TBL] [Abstract][Full Text] [Related]
30. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
31. Dopamine Replacement Medication Does Not Influence Implicit Learning of a Stepping Task in People With Parkinson's Disease.
Paul SS; Schaefer SY; Olivier GN; Walter CS; Lohse KR; Dibble LE
Neurorehabil Neural Repair; 2018 Dec; 32(12):1031-1042. PubMed ID: 30409107
[TBL] [Abstract][Full Text] [Related]
32. Decomposing effects of dopaminergic medication in Parkinson's disease on probabilistic action selection--learning or performance?
Smittenaar P; Chase HW; Aarts E; Nusselein B; Bloem BR; Cools R
Eur J Neurosci; 2012 Apr; 35(7):1144-51. PubMed ID: 22487043
[TBL] [Abstract][Full Text] [Related]
33. Motivational modes and learning in Parkinson's disease.
Foerde K; Braun EK; Higgins ET; Shohamy D
Soc Cogn Affect Neurosci; 2015 Aug; 10(8):1066-73. PubMed ID: 25552569
[TBL] [Abstract][Full Text] [Related]
34. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
Evens R; Hoefler M; Biber K; Lueken U
Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
[TBL] [Abstract][Full Text] [Related]
35. Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease.
Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA
Neuropsychologia; 2004; 42(14):1917-26. PubMed ID: 15381022
[TBL] [Abstract][Full Text] [Related]
36. Impulse control disorder in Parkinson's disease is associated with abnormal frontal value signalling.
Tichelaar JG; Sayalı C; Helmich RC; Cools R
Brain; 2023 Sep; 146(9):3676-3689. PubMed ID: 37192341
[TBL] [Abstract][Full Text] [Related]
37. Sequential movement skill in Parkinson's disease: a state-of-the-art.
Ruitenberg MF; Duthoo W; Santens P; Notebaert W; Abrahamse EL
Cortex; 2015 Apr; 65():102-12. PubMed ID: 25681652
[TBL] [Abstract][Full Text] [Related]
38. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.
Hälbig TD; Assuras S; Creighton J; Borod JC; Tse W; Frisina PG; Voustianiouk A; Gracies JM; Olanow CW
Mov Disord; 2011 Aug; 26(9):1677-83. PubMed ID: 21638322
[TBL] [Abstract][Full Text] [Related]
39. Distinct effects of dopamine vs STN stimulation therapies in associative learning and retention in Parkinson disease.
Ventre-Dominey J; Mollion H; Thobois S; Broussolle E
Behav Brain Res; 2016 Apr; 302():131-41. PubMed ID: 26778783
[TBL] [Abstract][Full Text] [Related]
40. By carrot or by stick: cognitive reinforcement learning in parkinsonism.
Frank MJ; Seeberger LC; O'reilly RC
Science; 2004 Dec; 306(5703):1940-3. PubMed ID: 15528409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
